Showing 1388 results
-
Press release /Detailed results from Phase II study in chronic migraine prevention showed patients on AMG 334 (erenumab) were significantly more likely to experience a 50% or more reduction in monthly migraine…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating income…
-
Story /Novartis researchers are collaborating with tech startup PathAI to search for hidden information in pathology slides.
-
Press release /Periodic Fever Syndromes are rare diseases mostly affecting children[1] and cause recurrent and disabling fevers with potentially life-threatening complications[2] Ilaris® (canakinumab) is…
-
Press release /Orphan drug designation is reserved for medicines treating rare, life-threatening or chronically debilitating diseases IgA nephropathy (IgAN), while rare, is the most common form of…
-
Ad hoc release /Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic…
-
Press release /Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine Erelzi is approved for all indications included in the reference product's…
-
Press release /Innovative AcrySof® IQ PanOptix® Toric intraocular lens (IOL) extends Alcon's trifocal PanOptix® IOL portfolio to a wider range of patients CE-marked in November 2016, this IOL offers…
-
Press release /AutonoMe(TM) preloaded IOL delivery system provides easy, intuitive control for precise IOL insertion during cataract surgery New Clareon® IOL in vitro data and early clinical experience to…
-
Press release /Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA…